News Conference News AHA 2024 ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS Michael O'Riordan November 21, 2024
News Conference News AHA 2024 Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360 Michael O'Riordan November 18, 2024
News Conference News AHA 2022 Common ‘Heart’ Supplements Can’t Beat Statins: SPORT Michael O'Riordan November 06, 2022
News Conference News AHA 2021 ApoB Gains Ground as Best Lipid Predictor of MI Risk Michael O'Riordan November 22, 2021
News Opinion Editor's Corner AHA 2021 AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More Shelley Wood November 08, 2021
News Conference News AHA 2020 OMEMI: Omega-3 Fatty Acids No Help in Elderly MI Patients Todd Neale November 15, 2020
News Conference News AHA 2020 Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol Michael O'Riordan November 12, 2020
News Conference News AHA 2019 Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE Yael L. Maxwell November 21, 2019
News Conference News AHA 2018 Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study Michael O'Riordan November 15, 2018
News Conference News AHA 2018 AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City Shelley Wood November 05, 2018
News Conference News AHA 2017 Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins Caitlin E. Cox November 14, 2017
News Conference News AHA 2015 Knowing Genetic Risk for MI Motivates Patients, Physicians to Get Cholesterol Levels Lower Yael L. Maxwell November 08, 2015